# The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin

> **NCT00031343** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 128 (—)

## Conditions studied

- HIV Infections
- Hepatitis C

## Interventions

- **DRUG:** highly active antiretroviral therapy (HAART)

## Key facts

- **NCT ID:** NCT00031343
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** —
- **Final completion:** 2004-04
- **Target enrollment:** 128 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00031343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00031343, "The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00031343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*